第一作者机构:[1]Capital Med Univ, Beijing Key Lab Pediat Hematol Oncol, Beijing, Peoples R China[2]Capital Med Univ, Natl Key Discipline Pediat, Beijing, Peoples R China[3]Capital Med Univ, Natl Ctr Childrens Hlth, Beijing Childrens Hosp, Key Lab Major Dis Children,Minist Educ, Beijing, Peoples R China[4]Capital Med Univ, Natl Ctr Childrens Hlth, Beijing Childrens Hosp, Hematol Oncol Ctr, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Wei Ang,Ma Hong-hao,Zhang Li-ping,et al.CLINICAL ANALYSIS OF RUXOLITINIB IN THE TREATMENT OF RECURRENT AND REFRACTORY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN[J].PEDIATRIC BLOOD & CANCER.2020,67:S37-S37.
APA:
Wei, Ang,Ma, Hong-hao,Zhang, Li-ping,Yang, Ying,Zhang, Rui&Wang, Tian-you.(2020).CLINICAL ANALYSIS OF RUXOLITINIB IN THE TREATMENT OF RECURRENT AND REFRACTORY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN.PEDIATRIC BLOOD & CANCER,67,
MLA:
Wei, Ang,et al."CLINICAL ANALYSIS OF RUXOLITINIB IN THE TREATMENT OF RECURRENT AND REFRACTORY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN CHILDREN".PEDIATRIC BLOOD & CANCER 67.(2020):S37-S37